<DOC>
	<DOCNO>NCT00057720</DOCNO>
	<brief_summary>The purpose study demonstrate superiority survival favor TLK286 compare active control therapy Doxil/Caelyx Hycamtin intent-to-treat ( ITT ) population .</brief_summary>
	<brief_title>TLK286 ( Telcyta ) vs. Doxil/Caelyx Hycamtin Platinum Refractory Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion criterion include : Considered platinum refractory resistant accord standard criterion Progressed follow completion one secondline treatment Doxil/Caelyx Hycamtin Histologically cytologically confirm diagnosis epithelial cancer ovary , fallopian tube , primary peritoneal cancer Measurable disease accord RECIST criterion document tumor progression Exclusion criterion include : Treatment secondline chemotherapy Doxil/Caelyx Hycamtin History whole pelvis radiation therapy within 12 month enrollment Clinically significant cardiac disease Evidence gross hematuria time study entry Any sign intestinal obstruction interfere nutrition time study entry Pregnant lactating woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>ovary</keyword>
</DOC>